The Hydration Pharmaceuticals Company Limited (ASX:HPC)

ALERT: Price-sensitive ASX Announcement for HPC

Current share price for HPC : $0.005 0.001 (25%)⁺

Announcement

Q2 FY26 Quarterly Activities Report (App 4C)

Release

31 Jul 2026 2:14PM

Price at Release

$0.004

Full Release

Summary

The Hydration Pharmaceuticals Company Limited (Hydralyte USA) reported a solid improvement in its Q2 FY26 performance, characterized by a 13.6% increase in net sales to US$695,566 compared to the previous quarter. The company focused on operational efficiency, achieving a 45% reduction in net cash used in operating activities, down to US$334,000. Cost-saving measures included a significant reduction in advertising and marketing expenditure and a restructuring that included headcount reductions. A capital raise completed in June 2026 brought in A$392,000, positioning the company for potential strategic acquisitions. The management anticipates further cost reductions and is committed to maintaining sales performance while evaluating options to enhance shareholder value.

Key Points

Net sales increased by 13.6% to US$695,566.
Operating activities cash usage reduced by 45%.
Advertising expenses to decrease from 42% to 32% of revenue.
Cost-saving measures include a US$360,000 annual reduction.
Successful capital raise of A$392,000 completed.
Continued focus on sales performance and shareholder value.
Evaluation of potential strategic acquisitions.

IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.